Jefferies Financial Group’s Blueprint Medicines BPMC Stock Holding History

Jefferies Financial Group’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-45,200	Closed	-$4M	–	1329
2025 Q1	$4M	Sell	45,200 -2,300	-5%	-$224K	0.04%	358
2024 Q4	$4.14M	Sell	47,500 -2,023	-4%	-$185K	0.02%	427
2024 Q3	$4.58M	Buy	49,523 +47,017	+1,876%	+$4.67M	0.03%	334
2024 Q2	$270K	Sell	2,506 -82	-3%	-$8.21K	﹤0.01%	1139
2024 Q1	$245K	Sell	2,588 -14,294	-85%	-$1.23M	﹤0.01%	1276
2023 Q4	$1.56M	Buy	16,882 +4,355	+35%	+$282K	0.01%	805
2023 Q3	$629K	Buy	12,527 +5,280	+73%	+$282K	0.01%	984
2023 Q2	$458K	Buy	7,247 +1,432	+25%	+$77.8K	﹤0.01%	1204
2023 Q1	$262K	Buy	5,815 +337	+6%	+$15.2K	﹤0.01%	1272
2022 Q4	$240K	Buy	+5,478	New	+$263K	﹤0.01%	1254

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jefferies Financial Group's BPMC Position: Q2 2025 in Review

Jefferies Financial Group sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 45,200 shares — an estimated $4M sold.

Jefferies Financial Group first reported a position in BPMC in Q4 2022 and held it in 10 quarters. The position peaked at $4.58M in Q3 2024. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

Jefferies Financial Group reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
Jefferies Financial Group sold 45,200 Blueprint Medicines shares in Q2 2025, an estimated $4M.
Jefferies Financial Group first reported a position in Blueprint Medicines in Q4 2022 and held it in 10 quarters.
Jefferies Financial Group's Blueprint Medicines position peaked at $4.58M in Q3 2024.
354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Jefferies Financial Group's 13F filing for Q2 2025, filed 12 Aug 2025.